Keytruda Combo Improves Development, Survival in Recurrent Ovarian Most cancers

Amongst sufferers with platinum-resistant recurrent ovarian most cancers (PRROC), the remedy mixture of Keytruda (pembrolizumab) with weekly paclitaxel with or with out Avastin (bevacizumab) was related to important enhancements in progression-free survival (PFS) no matter PD-L1 standing and total survival (OS), medical trial outcomes have proven.

Findings from the part 3 ENGOT-ov65/KEYNOTE-B96 trial have been shared on the European Society of Medical Oncology Congress 2025.

The evaluation was damaged down between the inhabitants of sufferers with a mixed optimistic rating (CPS) of 1 or larger and the intention-to-treat inhabitants. Moreover, information have been damaged down between interim evaluation 1 (IA1), which had a knowledge cutoff date of April 3, 2024, and interim evaluation 2 (IA2), which had a knowledge cutoff date of Might 5, 2025.

The CPS of 1 or Larger Inhabitants

At IA1, the median PFS was 8.3 months within the Keytruda arm in contrast with 7.2 months within the placebo arm, with 12-month PFS charges of 35.2% versus 22.6%, respectively.

At IA2, the median PFS was 8.3 months within the Keytruda arm in contrast with 7.2 months within the placebo arm; the 12-month PFS charges have been 35.9% versus 23.9%, respectively, and the 18-month charges have been 18.7% versus 10.5%.

The median OS was 18.2 months within the Keytruda arm in contrast with 14 months within the placebo arm, with 12-month OS charges of 69.1% versus 59.3%, and 18-month OS charges of 51.5% versus 38.9%, respectively.

The target response price (ORR) was 53% with a whole response (CR) price of 9.9% and a partial response (PR) price of 43.1%, within the Keytruda arm; within the placebo arm, the ORR was 46.6%, with a CR price of seven.8% and a PR price of 38.7%. The 12- and 18-month period of response (DOR) charges within the Keytruda arm have been 46.7% and 28.4% in contrast with 29.6% and 16.4% within the placebo arm.

The ITT Inhabitants

At IA1, the median PFS was 8.3 months with Keytruda in contrast with 6.4 months with placebo, with 12-month PFS charges of 33.1% and 21.3%, respectively.

At IA2, the median PFS was 8.3 months versus 6.4 months, respectively; the 12-month PFS charges have been 33.7% versus 22.5%, and the 18-month PFS charges have been 17.3% versus 9%.

The ORR was 50.4%, with a CR price of 8.3% and a PR price of 42%, within the Keytruda arm; within the placebo arm, the ORR was 40.8%, with a CR price of 6% and a PR price of 34.8%.Moreover, the 12- and 18-month DOR charges within the Keytruda arm have been 46.6% and 26.5% in contrast with 28.4% and 14.5% within the placebo arm.

“These information assist using [Keytruda] plus weekly paclitaxel, with or with out [Avastin], as a brand new normal of take care of sufferers with PRROC,” presenting creator Dr. Nicoletta Colombo of the Gynecologic Oncology Program on the European Institute of Oncology, IRCCS, in Milan, Italy, and the Division of Medication and Surgical procedure on the College of Milan-Bicocca in Italy, wrote with coauthors within the presentation.

Security Analyses

Any-grade treatment-related unwanted side effects occurred in 97.8% of the Keytruda arm and 95.3% of the placebo arm; grade 3 (extreme) or larger treatment-related unwanted side effects occurred in 67.5% and 55.3%, respectively. Remedy-related unwanted side effects have been critical in 33.1% and 19.5%, led to loss of life in 0.9% and 1.6%, and led to discontinuation of any remedy in 35.9% and 28%.

Any-grade immune-mediated unwanted side effects occurred in 39.1% and 18.9%, and grade 3 or larger occasions occurred in 11.6% and three.5%. They have been critical occasions in 10.9% and a couple of.2%, and led to remedy discontinuation in 6.9% and a couple of.5%.

The commonest treatment-related unwanted side effects in each teams included anemia (49.7% versus 42.1%, respectively), peripheral neuropathy (38.8% versus 31.1%), alopecia (37.8% versus 34%), fatigue (35.3% versus 33%) and nausea (31.3% versus 27.4%). The commonest immune-mediated unwanted side effects have been hypothyroidism (17.8% versus 6%), infusion reactions (5.9% versus 4.7%) and hyperthyroidism (5% versus 0.6%).

Trial Breakdown

A complete of 643 sufferers with histologically confirmed epithelial ovarian, fallopian tube or main peritoneal carcinoma have been enrolled within the trial and randomly assigned to both the Keytruda arm (322 sufferers) or the placebo arm (321 sufferers). Remedy was both Keytruda at 400 mg as soon as each six weeks for 18 cycles or placebo on the identical schedule; all sufferers obtained paclitaxel at 80 mg/m² on days 1, 8, and 15 of every three-week-long cycle, they usually both did or didn’t obtain Avastin at 10 mg/kg each 2 weeks.

Sufferers have been enrolled within the trial if they’d obtained one or two prior strains of remedy with not less than one platinum-based chemotherapy; prior anti-PD-1 or anti-PD-L1 brokers, PARP inhibitors and Avastin have been permitted. Moreover, sufferers had radiographic development inside six months after the final dose of platinum-based chemotherapy and an ECOG efficiency standing of 0 or 1.

The median age of sufferers was 62 years versus 61 years within the Keytruda versus placebo arm, 64.3% and 67.6% of sufferers have been White, 41.3% and 41.1% had a PD-L1 CPS from 1 to lower than 10, and 31.4% and 31.2% had a PD-L1 CPS of not less than 10.

Reference

1. “Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian most cancers: Outcomes from the randomized double-blind part 3 ENGOT-ov65/KEYNOTE-B96 examine,” by Dr. Nicoletta Colombo. Offered at: European Society of Medical Oncology Congress 2025; October 17–20, 2025; Berlin, Germany. Summary LBA3.

For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.